The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations
Excerpt:
Potent antitumor activity against tumors with PIK3CA mutations was also evident in the ovarian cancer SK-OV-3 and endometrial cancer MFE-280 models (Fig. 3C).